(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
28 June 2007 (28.06.2007)

PCT

(10) International Publication Number
WO 2007/072095 A1

(51) International Patent Classification:
C07D 495/04 (2006.01) *A61P 25/00* (2006.01)
A61K 31/4365 (2006.01)

(21) International Application Number:
PCT/HU2006/000123

(22) International Filing Date:
19 December 2006 (19.12.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
P05 01171 20 December 2005 (20.12.2005) HU
P06 00920 18 December 2006 (18.12.2006) HU

(71) Applicant *(for all designated States except US)*: **RICHTER GEDEON VEGYÉSZETI GYÁR RT.** [HU/HU]; Gyömröi út 19-21, H-1103 Budapest (HU).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **NÓGRÁDI, Katalin** [HU/HU]; Kossuth Lajos u. 145/A, H-1182 Budapest (HU). **WÁGNER, Gábor** [HU/HU]; Kazinczy u. 2., H-1191 Budapest (HU). **KESERÜ, György** [HU/HU]; Berkenye u. 9, H-2089 Telki (HU). **BIELIK, Attila** [HU/HU]; Táncsics Mihály út 68, H-2377 Örkény (HU). **GÁTI, Tamás** [HU/HU]; Bartók Béla út 15/B, H-1114 Budapest (HU). **HÁDA, Viktor** [HU/HU]; Gergely u. 128. A/52, H-1108 Budapest (HU). **KÓTI, János** [HU/HU]; Benczúr Gyula u. 18, H-4440 Tiszavasvári (HU). **GÁL, Krisztina** [HU/HU]; Táncsics Mihály u. 38, H-1193 Budapest (HU). **VASTAG, Mónika** [HU/HU]; Rómer Flóris u. 26, H-1024 Budapest (HU). **BOBOK, Amrita, Ágnes** [HU/HU]; Csalán u. 49/B, H-1025 Budapest (HU).

(74) Common Representative: **RICHTER GEDEON VEGYÉSZETI GYÁR RT.**; Gyömröi út 19-21, H-1103 Budapest (HU).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declaration under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:
— *with international search report*

[Continued on next page]

(54) Title: NEW COMPOUNDS



(I)

(57) **Abstract:** The present invention relates to new mGluRl and mGluR5 receptor subtype preferring ligands of formula (I) wherein X represents a group selected from SO, SO2; Y represents a group selected from $(CH_2)_n$, NH, $NHCH_2$; n is an integer of 0 to 1; Z is H or monosubstituted by alkyl, nitro, halogen, alkoxy, trifluoromethyl, cyano, amino, alkylamino, dialkylamino, aminomethyl, alkylaminomethyl, dialkylaminomethyl, hydroxyl, alkylsulfonylamino; R_1 is an optionally substituted alkyl, cycloalkyl, phenyl, biphenyl, heterocyclyl; R_2 is an optionally substituted phenyl, heterocyclyl, or NR_3R_4 group wherein R_3 and R_4 are independently selected from the group of hydrogen and an optionally substituted alkyl, or R_3 and R_4 together with the N atom to which they are attached form an optionally substituted C_{5-7} heterocyclyl group, containing one or more heteroatom(s), or NH-CO-NR_5R_6 group, wherein R_5 and R_6 are independently selected from the group of hydrogen and an optionally substituted alkyl, or R_5 and R_6 together with the N atom to which they are attached form an optionally substituted C_{5-7} heterocyclyl group, containing one or more heteroatom(s); and/or hydrates and/or solvates and/or pharmaceutically acceptable salts thereof formed with acids or bases, to the processes for producing the same, to pharmaceutical compositions containing the same and to their use in therapy and/or prevention of pathological conditions which require the modulation of mGluRl and mGluR5 receptors such as neurological disorders, psychiatric disorders, acute and chronic pain, neuromuscular dysfunctions of the lower urinary tract and gastrointestinal disorders.

WO 2007/072095 A1

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.